Standard BioTools Inc.
LAB
$1.01
$0.000.00%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -11.13% | 21.70% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -11.13% | 21.70% | |||
| Cost of Revenue | -4.99% | 23.29% | |||
| Gross Profit | -17.83% | 20.01% | |||
| SG&A Expenses | -26.56% | -4.73% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -33.15% | 6.28% | |||
| Operating Income | 57.05% | 6.58% | |||
| Income Before Tax | 33.66% | 33.04% | |||
| Income Tax Expenses | 100.03% | -2,854.93% | |||
| Earnings from Continuing Operations | -205.22% | 143.87% | |||
| Earnings from Discontinued Operations | 2,532.74% | 279.22% | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 558.96% | 155.59% | |||
| EBIT | 57.05% | 6.58% | |||
| EBITDA | 51.87% | 23.92% | |||
| EPS Basic | 553.29% | 155.24% | |||
| Normalized Basic EPS | 47.98% | 35.25% | |||
| EPS Diluted | 553.29% | 155.24% | |||
| Normalized Diluted EPS | 47.98% | 35.25% | |||
| Average Basic Shares Outstanding | 0.82% | 0.63% | |||
| Average Diluted Shares Outstanding | 0.82% | 0.63% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||